ロード中...
TERT and DNMT1 expression predict sensitivity to decitabine in gliomas
BACKGROUND: Decitabine (DAC) is an FDA-approved DNA methyltransferase (DNMT) inhibitor that is used in the treatment of patients with myelodysplastic syndromes. Previously, we showed that DAC marks antitumor activity against gliomas with isocitrate dehydrogenase 1 (IDH1) mutations. Based on promisin...
保存先:
| 出版年: | Neuro Oncol |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7850113/ https://ncbi.nlm.nih.gov/pubmed/32882013 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa207 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|